🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 05156V102
- Market Cap
- Mid Cap
- Previous Symbol
- IPHAF (changed 9/2/2014)
Business: Aurinia Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to endstage renal disease, making LN a serious and potentially life-threatening condition.
Company Contact
- CEO
- Peter Greenleaf
- CFO
- Joe Miller
- Headquarters
- #140, 14315 -118 Avenue, Edmonton, Alberta T5L 4S6
- Phone
- 250-744-2487
- Fax
- 250-744-2498
- Investor Relations
- Andrea Christopher · 250-708-4272 · achristopher@auriniapharma.com